BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38200511)

  • 1. Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics.
    Yolchuyeva S; Ebrahimpour L; Tonneau M; Lamaze F; Orain M; Coulombe F; Malo J; Belkaid W; Routy B; Joubert P; Manem VS
    J Transl Med; 2024 Jan; 22(1):42. PubMed ID: 38200511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study.
    Yolchuyeva S; Giacomazzi E; Tonneau M; Lamaze F; Orain M; Coulombe F; Malo J; Belkaid W; Routy B; Joubert P; Manem VSK
    Sci Rep; 2023 Jul; 13(1):11065. PubMed ID: 37422576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Radiomics-Clinical Model Predicts Overall Survival of Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: A Multicenter Study.
    Yolchuyeva S; Giacomazzi E; Tonneau M; Ebrahimpour L; Lamaze FC; Orain M; Coulombe F; Malo J; Belkaid W; Routy B; Joubert P; Manem VSK
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study.
    Yolchuyeva S; Giacomazzi E; Tonneau M; Lamaze F; Orain M; Coulombe F; Malo J; Belkaid W; Routy B; Joubert P; Manem VSK
    JTO Clin Res Rep; 2023 Dec; 4(12):100602. PubMed ID: 38124790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
    Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
    Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer.
    Gong J; Bao X; Wang T; Liu J; Peng W; Shi J; Wu F; Gu Y
    Oncoimmunology; 2022; 11(1):2028962. PubMed ID: 35096486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiomics of
    Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretherapy investigations using highly robust visualized biomarkers from CT imaging by multiple machine-learning techniques toward its prognosis prediction for ALK-inhibitor therapy in NSCLC: a feasibility study.
    Sun J; Li F; Yang J; Lin C; Zhou X; Liu N; Zhang B; Song G; Wang W; Huang C; Song Z; Shi L
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7341-7353. PubMed ID: 36928998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalization optimizing machine learning to improve CT scan radiomics and assess immune checkpoint inhibitors' response in non-small cell lung cancer: a multicenter cohort study.
    Tonneau M; Phan K; Manem VSK; Low-Kam C; Dutil F; Kazandjian S; Vanderweyen D; Panasci J; Malo J; Coulombe F; Gagné A; Elkrief A; Belkaïd W; Di Jorio L; Orain M; Bouchard N; Muanza T; Rybicki FJ; Kafi K; Huntsman D; Joubert P; Chandelier F; Routy B
    Front Oncol; 2023; 13():1196414. PubMed ID: 37546399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing brain metastasis prediction in non-small cell lung cancer: a deep learning-based segmentation and CT radiomics-based ensemble learning model.
    Gong J; Wang T; Wang Z; Chu X; Hu T; Li M; Peng W; Feng F; Tong T; Gu Y
    Cancer Imaging; 2024 Jan; 24(1):1. PubMed ID: 38167564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Survival Prognostic Modelling of Non-small Cell Lung Cancer Patients Using Positron Emission Tomography/Computed Tomography Harmonised Radiomics Features: The Quest for the Optimal Machine Learning Algorithm.
    Amini M; Hajianfar G; Hadadi Avval A; Nazari M; Deevband MR; Oveisi M; Shiri I; Zaidi H
    Clin Oncol (R Coll Radiol); 2022 Feb; 34(2):114-127. PubMed ID: 34872823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inconsistent CT NSCLC radiomics associated with feature selection methods, predictive models and related factors.
    Ge G; Siddique A; Zhang J
    Phys Med Biol; 2023 Jun; 68(12):. PubMed ID: 37072008
    [No Abstract]   [Full Text] [Related]  

  • 14. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
    Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer.
    Tunali I; Tan Y; Gray JE; Katsoulakis E; Eschrich SA; Saller J; Aerts HJWL; Boyle T; Qi J; Guvenis A; Gillies RJ; Schabath MB
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.
    Mu W; Katsoulakis E; Whelan CJ; Gage KL; Schabath MB; Gillies RJ
    Br J Cancer; 2021 Jul; 125(2):229-239. PubMed ID: 33828255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of an MRI-Based nomogram to predict the effectiveness of immunotherapy for brain metastasis in patients with non-small cell lung cancer.
    Xu J; Wang P; Li Y; Shi X; Yin T; Yu J; Teng F
    Front Immunol; 2024; 15():1373330. PubMed ID: 38686383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
    Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
    J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of feature selection methods and subgroup factors on prognostic analysis with CT-based radiomics in non-small cell lung cancer patients.
    Sugai Y; Kadoya N; Tanaka S; Tanabe S; Umeda M; Yamamoto T; Takeda K; Dobashi S; Ohashi H; Takeda K; Jingu K
    Radiat Oncol; 2021 Apr; 16(1):80. PubMed ID: 33931085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomics feature analysis and model research for predicting histopathological subtypes of non-small cell lung cancer on CT images: A multi-dataset study.
    Song F; Song X; Feng Y; Fan G; Sun Y; Zhang P; Li J; Liu F; Zhang G
    Med Phys; 2023 Jul; 50(7):4351-4365. PubMed ID: 36682051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.